The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Excessive arousal has a role in the pathophysiology of major depressive disorder (MDD). Seltorexant (JNJ-42847922/MIN-202) is a selective antagonist of the human orexin-2 receptor (OX2R) that may normalize excessive arousal and thereby attenuate depressive symptoms. In this study, the effects of night-time arousal suppression on depressive symptoms were investigated. 47 MDD patients with a total Inventory of Depressive Symptomatology (IDS) score of ≥30 at screening were included in a randomized, double-blind, diphenhydramine-, and placebo-controlled multicentre study. Symptoms of depression were rated using the 17-item Hamilton Depression Rating Scale (HDRS 17). Effects on sleep were evaluated by polysomnography and by the Leeds Sleep Evaluation Questionnaire (LSEQ). To investigate the safety and tolerability of seltorexant, vital signs, suicidal ideation and adverse events were monitored. At baseline the severity of depressive symptoms correlated with sleep efficiency (SE), wake after sleep onset (WASO), duration of stage 2 sleep, and ruminations. Ten days of treatment with seltorexant (and not diphenhydramine) resulted in a significant improvement of core depressive symptoms compared to placebo; the antidepressant efficacy of seltorexant was maintained with continued treatment up to 28 days. Compared to placebo, the antidepressant efficacy of seltorexant coincided with an overall increase in (left posterior) EEG power and a relative increase in delta- and decrease in theta-, alpha- and beta power during stage 2 sleep. Treatment with seltorexant was associated with mild, self-limiting adverse drug reactions. Seltorexant affected core symptoms of depression in the absence of overt changes in the hypnogram; in contrast, diphenhydramine was not efficacious.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Narcolepsy in orexin Knockout Mice
Chemelli, R. M., Willie, J. T., Sinton, C. M., Elmquist, J. K., Scammell, T., Lee, C., Richardson, J. A., Williams, S. C., Xiong, Y., Kisanuki, Y., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)81973-x · Cited by 3,095
Sleep disturbance and psychiatric disorders: A longitudinal epidemiological study of young Adults
Breslau, N., Roth, T., Rosenthal, L., & Andreski, P. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00188-3 · Cited by 1,831
Gold, P. W., & Chrousos, G. P. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001032 · Cited by 1,274
TRIVEDI, M. H., RUSH, A. J., IBRAHIM, H. M., CARMODY, T. J., BIGGS, M. M., SUPPES, T., CRISMON, M. L., SHORES-WILSON, K., TOPRAC, M. G., DENNEHY, E. B., et al. (2004) · Psychological Medicine · doi:10.1017/s0033291703001107 · Cited by 968
Johnson, E. O., Roth, T., & Breslau, N. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.07.008 · Cited by 804
Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression
Drevets, W. C. (2000) · Progress in Brain Research · doi:10.1016/s0079-6123(00)26027-5 · Cited by 659
Self-citationJansson-Fröjmark, M., & Lindblom, K. (2008) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2007.10.016 · Cited by 646
Distinct Narcolepsy Syndromes in Orexin Receptor-2 and Orexin Null Mice
Willie, J. T., Chemelli, R. M., Sinton, C. M., Tokita, S., Williams, S. C., Kisanuki, Y. Y., Marcus, J. N., Lee, C., Elmquist, J. K., Kohlmeier, K. A., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00330-1 · Cited by 645
Serotonin-1A receptor imaging in recurrent depression: replication and literature review
Drevets, W. C., Thase, M. E., Moses-Kolko, E. L., Price, J., Frank, E., Kupfer, D. J., & Mathis, C. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.06.008 · Cited by 399
Self-citationCuijpers, P., Li, J., Hofmann, S. G., & Andersson, G. (2010) · Clinical Psychology Review · doi:10.1016/j.cpr.2010.06.001 · Cited by 383
Cited by
The stressed synapse 2.0: pathophysiological mechanisms in stress-related neuropsychiatric disorders
Sanacora, G., Yan, Z., & Popoli, M. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00540-x · Cited by 197
Clinical specificity profile for novel rapid acting antidepressant drugs
Scala, M., Fanelli, G., De Ronchi, D., Serretti, A., & Fabbri, C. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000488 · Cited by 41
Hypothalamic stress systems in mood disorders
(2021) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-819973-2.00003-4 · Cited by 15
von Spreckelsen, P., Schouten, D., Waslam, N. G., Katuin, P., Heering, H. D., Planting, C., Antypa, N., Kivelä, L., Lancel, M., & Schweren, L. J. S. (2025) · Sleep Medicine: X · doi:10.1016/j.sleepx.2025.100145 · Cited by 7
“Another study reported no suicides in either the seltorexant nor the placebo control group [86].”
Influential
Metadata
- Authors
- Recourt, K., de Boer, P., Zuiker, R., Luthringer, R., Kent, J., van der Ark, P., Van Hove, I., van Gerven, J., Jacobs, G., van Nueten, L., & Drevets, W.
- Venue
- Translational Psychiatry
- Published
- 2019-09-03
- Volume
- 9
- Issue
- 1
- Pages
- 216-216
- ISSN
- 2158-3188 (ISSN-L)
- OpenAlex
- W2971807108
- Cited by
- 86
- References
- 15
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder. https://app.cochat.ai/papers/10.1038/s41398-019-0553-z
- The paper
- Recourt, K., de Boer, P., Zuiker, R., Luthringer, R., Kent, J., van der Ark, P., Van Hove, I., van Gerven, J., Jacobs, G., van Nueten, L., & Drevets, W. (2019). The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder. Translational Psychiatry. https://doi.org/10.1038/s41398-019-0553-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.